Breast cancer

Munich Re Life US and the American Cancer Society Support Early-Stage Investigators at Leading Health Institutions

Retrieved on: 
Wednesday, March 10, 2021
Professional services, Oncology, Health, Insurance, Finance, Pharmaceutical, Cancer, Breast cancer, American Cancer Society, Health, Causes of death, Clinical medicine, Munich Re Life US, Munich Re, the American Cancer Society

Munich Re Life US is pleased to help fund two critical American Cancer Society (ACS) Research Scholar Grants that focus on increasing the survival rates amongst breast cancer patients.

Key Points: 
  • Munich Re Life US is pleased to help fund two critical American Cancer Society (ACS) Research Scholar Grants that focus on increasing the survival rates amongst breast cancer patients.
  • Overweight and obesity affect more than two-thirds of Americans and are now leading modifiable lifestyle factors that increase the risk of cancer and cancer relapse.
  • Munich Re Life US is proud to support the ACS and the brilliant work of individuals like Dr. Iyengar and Dr. Hazra who are leading the next generation of cancer research, said Marc Giguere, President & Chief Executive Officer, Munich Re US, Life & Health.
  • The American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.

John E. Kehoe, MD is recognized by Continental Who's Who

Retrieved on: 
Wednesday, March 10, 2021
Breast cancer, Clinical medicine, Medicine, Health, Breast surgery, Cancer, Breast implant, Christobel Saunders

Avenue, Dr. John Kehoe Breast Center is an innovative breast center facility in Brooklyn that has provided comprehensive breast medical care from screening and diagnosis to breast cancer treatment.

Key Points: 
  • Avenue, Dr. John Kehoe Breast Center is an innovative breast center facility in Brooklyn that has provided comprehensive breast medical care from screening and diagnosis to breast cancer treatment.
  • For years, the center has been built on the foundation that every woman should have a specialized breast doctor as she has a gynecologist.
  • Treatment plans are created according to each patient's routine breast care, or diagnosis from Breast Cancer treatments to benign breast conditions.
  • Renowned board-certified breast cancer surgeon and surgical oncologist, Dr. Kehoe has garnered decades of extensive training and professional experience.

Solis Mammography Announces Expansion Into Southeast Florida Market

Retrieved on: 
Wednesday, March 10, 2021
Cancer screening, Breast imaging, Mammography, Projectional radiography, Clinical medicine, Medicine, Breast cancer

Both physicians are graduates of the University of Miami School of Medicine, with fellowships in breast imaging from Mt.

Key Points: 
  • Both physicians are graduates of the University of Miami School of Medicine, with fellowships in breast imaging from Mt.
  • We have a mutual dedication to delivering an exceptional experience, said Grant Davies, president and Chief Executive Officer of Solis Mammography.
  • We chose Solis Mammography as our breast health partner so we could improve operational efficiencies in order to serve more patients, said Art Mesa, executive director and co-founder of Miami Breast Institute.
  • Solis Mammographys partnership with Miami Breast Institute expands its footprint into its 10th major market.

AHN Cancer Institute Opens Genomics Facility Offering Patients Next-Generation Gene Sequencing to Guide Treatment Decisions

Retrieved on: 
Tuesday, March 9, 2021
Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Infectious causes of cancer, Breast cancer, Treatment of cancer, Metástasis, Targeted therapy, Colorectal cancer, Personalized onco-genomics, Molecular diagnostics

The Clinical Genomics Laboratory will provide next-generation gene sequencing based on blood or tumor samples from patients with metastatic (late-stage) cancer, and a variety of common early-stage cancers including breast, colon and lung cancer.

Key Points: 
  • The Clinical Genomics Laboratory will provide next-generation gene sequencing based on blood or tumor samples from patients with metastatic (late-stage) cancer, and a variety of common early-stage cancers including breast, colon and lung cancer.
  • "The advent of genomic testing and targeted therapies over the past several years has changed the face of cancer treatment," said David Bartlett, MD , chair, AHN Cancer Institute.
  • The growth of cancer cells is fueled by genetic abnormalities, such as malfunction of genes that prevent cancer, or that spark the growth of cancer cells.
  • AHN also has a formal affiliation with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, one of the nation's 41 comprehensive cancer centers designated by the National Cancer Institute, for research, medical education and clinical services.

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, March 9, 2021
Breast cancer, Triple-negative breast cancer, Prostate cancer, Management of prostate cancer, Cancer, Anatomy, Health

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference.

Key Points: 
  • MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference.
  • The presentation will be available through the Conference on Tuesday, March 16th at 3:10 p.m.
  • Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer.
  • The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk

Retrieved on: 
Monday, March 8, 2021
Oncology, Health, Other Science, Research, Science, Biotechnology, Breast cancer, Lymphology, Oncology, Sentinel lymph node, I31, DecisionDx-Melanoma, Castle Biosciences

The Company plans to launch an app later in 2021 for dermatology clinicians, featuring an interactive algorithm using the 31-GEP test score and traditional clinicopathologic factors to predict risk.

Key Points: 
  • The Company plans to launch an app later in 2021 for dermatology clinicians, featuring an interactive algorithm using the 31-GEP test score and traditional clinicopathologic factors to predict risk.
  • We have demonstrated our ability to bring high value, clinically actionable genomic tests to market, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • We recognize the complexity of cancer and the necessity of diagnostics to utilize advanced approaches to provide actionable results, as exemplified in the use of artificial intelligence for our i31-GEP and updated integrated patient test result.
  • To predict likelihood of sentinel lymph node positivity, the Company utilizes its proprietary algorithm, i31-GEP, to produce an integrated test result.

Study using Volpara Health's AI-powered image quality scoring wins Magna cum Laude award at ECR 2021

Retrieved on: 
Monday, March 8, 2021
Medicine, Clinical medicine, Cancer screening, Breast imaging, Projectional radiography, Mammography, Screening, Breast cancer, Technologist, Latin honors

Only eight were selected to win the top award of Magna cum Laude including a retrospective study examining the relationship between technical repeats from the UK NHS Breast Screening Program and Volpara's automated PGMI scoring.

Key Points: 
  • Only eight were selected to win the top award of Magna cum Laude including a retrospective study examining the relationship between technical repeats from the UK NHS Breast Screening Program and Volpara's automated PGMI scoring.
  • Images labeled inadequate are considered to be low in diagnostic quality and may be repeated by the technologist.
  • Notably, of the technical repeat cases, 53% of them received a higher score than the original image.
  • The results of this study highlight the role of artificial intelligence (AI) tools in providing objective image quality feedback independent of a mammography reader's training or background.

New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting

Retrieved on: 
Monday, March 8, 2021
Artificial intelligence, European Congress of Radiology, Breast cancer, Radiology, ICAD, Medicine, Health

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI was presented at the European Congress of Radiology ( ECR ) 2021 Online meeting, taking place March 3-10, 2021.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI was presented at the European Congress of Radiology ( ECR ) 2021 Online meeting, taking place March 3-10, 2021.
  • ProFound AI empowers doctors to find breast cancers earlier, when they may be more easily treated.
  • Furthermore, new research presented at ECR demonstrates how ProFound AI helps to improve radiologists workflow and efficiency.
  • When researchers also factored in breast density and age, ProFound AI identified up to 58.6 percent of normal cases with no false negatives.

Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

Retrieved on: 
Monday, March 8, 2021
Oncology, Health, Consumer, Women, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Health, Breast cancer, Medicine, Clinical trial, Iniparib, Buparlisib, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Dr. Thompson commented, I am excited to begin managing our Phase III clinical trial for recurring breast cancer.

Key Points: 
  • Dr. Thompson commented, I am excited to begin managing our Phase III clinical trial for recurring breast cancer.
  • Over 3 million U.S. breast cancer survivors need safe and effective drugs to prevent metastatic breast cancer recurrence.
  • I look forward to leveraging my prior experiences in protocol and trial design, clinical trial start-up activities, clinical trial management, statistical analysis of clinical and biomarker data, and management of relationships with U.S. and European regulators as we commence the GP2 Phase III trial.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Burt's Bees Launches Campaign to Support Women Facing Breast Cancer

Retrieved on: 
Monday, March 8, 2021
Skin care, Clothing, Fashion, Culture, Prosthetics, Hairdressing, Judicial clothing, Wig, Breast prostheses, Cosmetics, Burt's Bees, Breast cancer

TORONTO, March 8, 2021 /CNW/ - A leading personal care products company Burt's Bees has launched a campaign with Look Good Feel Better (LGFB) to celebrate and support women facing cancer.

Key Points: 
  • TORONTO, March 8, 2021 /CNW/ - A leading personal care products company Burt's Bees has launched a campaign with Look Good Feel Better (LGFB) to celebrate and support women facing cancer.
  • LGFB workshops help women learn techniques to manage the appearance-related side effects of cancer treatment with skincare, cosmetics, wigs, scarf-tying techniques, breast forms and garments, and more.
  • "The purpose of this video is to show the power of beauty and makeup in restoring self-confidence for women facing cancer.
  • Women facing cancer are welcome to register for all or one online workshop at lgfb.ca or by phone or 1-800-914-5665.